Investing.com - Bio Path reported on Tuesday third quarter earnings that missed analysts' forecasts and revenue that was inline with expectations.
Bio Path announced earnings per share of $-0.490 on revenue of $0.00. Analysts polled by Investing.com EPS of $-0.460 on revenue of $0.
Bio Path 's are down 59% and is trading at $1.530 , still down 71.02% from its 52 week high of $5.28 set on Monday, November 29, 2021.
Bio Path shares lost 3.77% to trade at $1.530 in intra-day trade the report.
Bio Path follows other major Healthcare sector earnings this month
Bio Path's report follows an earnings beat by J&J on Tuesday, October 18, 2022, who reported EPS of $2.55 on revenue of $23.79B, EPS of $2.48 on revenue of $23.36B.
Eli Lilly had beat expectations on Tuesday, November 1, 2022 with third quarter EPS of $1.98 on revenue of $6.94B, for EPS of $1.91 on revenue of $6.91B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar